Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Director | March 31, 2012 | April 03, 2012 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date March 31, 2012 · Filed April 03, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 21,966 |
Reported balance
After 2012-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2012-03-31 · Grant · Acquired 562 · Balance 21,966 F1: Director fees credited to a stock equivalent unit account established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. |
Filing footnotes · ownership attribution and instrument terms
F1: Director fees credited to a stock equivalent unit account established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock.
F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
JPMORGAN CHASE & CO
Report date July 15, 2003 · Filed August 01, 2003
Section 16 reporting ended · disclosed 2003-08-01. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 23, 2008 Filed Apr 25, 2008 20:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,526 | $50.59 | $178,394.44 |
DisclosureSEC source: 0001104659-08-026948 · a4.xml · nonDerivative · entry 2 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,544 Read SEC document |
| April 23, 2008 Filed Apr 25, 2008 20:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 5,124 | $33.95 | $173,961.34 |
DisclosureSEC source: 0001104659-08-026948 · a4.xml · nonDerivative · entry 1 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2008 Filed Apr 2, 2008 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock equivalent units · Derivative | 489 | $55.15 Strike: $0.00 | $26,968.35 |
DisclosureSEC source: 0001104659-08-022152 · a4.xml · derivative · entry 1 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,323 Underlying: Common Shares · 489 shares Expires not disclosed F1 · derivative.exercise_price: Director fees deferred and credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees deferred and credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees deferred and credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2007 Filed Jan 2, 2008 23:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock equivalent units · Derivative | 480 | $56.15 Strike: $0.00 | $26,952.00 |
DisclosureSEC source: 0001104659-08-000231 · a4.xml · derivative · entry 2 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,776 Underlying: common shares · 480 shares Expires not disclosed F1 · derivative.exercise_price: Director fees deferred and credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees deferred and credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees deferred and credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| November 26, 2007 Filed Jan 2, 2008 23:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 29,434 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-08-000231 · a4.xml · nonDerivative · entry 1 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,946 Read SEC document |
| September 30, 2007 Filed Oct 3, 2007 00:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock equivalent units · Derivative | 503 | $53.62 Strike: $0.00 | $26,970.86 |
DisclosureSEC source: 0001104659-07-072701 · a4.xml · derivative · entry 1 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,240 Underlying: common shares · 503 shares Expires not disclosed F1 · derivative.exercise_price: Director fees deferred and credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees deferred and credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees deferred and credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2007 Filed Jul 3, 2007 18:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock equivalent units · Derivative | 479 | $53.55 Strike: $0.00 | $25,650.45 |
DisclosureSEC source: 0001104659-07-052110 · a4.xml · derivative · entry 1 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,682 Underlying: common shares · 479 shares Expires not disclosed F1 · derivative.exercise_price: Director fees deferred and credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees deferred and credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees deferred and credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| April 27, 2007 Filed May 1, 2007 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon Shares without par value | 1,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-07-034486 · a4.xml · nonDerivative · entry 1 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,380 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| January 30, 2007 Filed Feb 1, 2007 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,881 | $0.00 Strike: $30.20 | $0.00 |
DisclosureSEC source: 0001104659-07-006560 · a4.xml · derivative · entry 12 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 2,881 shares Expires 2007-10-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program. It includes a replacement option feature. Read SEC document |
| January 30, 2007 Filed Feb 1, 2007 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,436 | $0.00 Strike: $30.24 | $0.00 |
DisclosureSEC source: 0001104659-07-006560 · a4.xml · derivative · entry 11 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 1,436 shares Expires 2007-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program. It includes a replacement option feature. Read SEC document |
| January 30, 2007 Filed Feb 1, 2007 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,383 | $0.00 Strike: $31.43 | $0.00 |
DisclosureSEC source: 0001104659-07-006560 · a4.xml · derivative · entry 10 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 1,383 shares Expires 2007-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program. It includes a replacement option feature. Read SEC document |
| January 30, 2007 Filed Feb 1, 2007 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,393 | $0.00 Strike: $26.88 | $0.00 |
DisclosureSEC source: 0001104659-07-006560 · a4.xml · derivative · entry 9 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 1,393 shares Expires 2007-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program. It includes a replacement option feature. Read SEC document |
| January 30, 2007 Filed Feb 1, 2007 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,881 | $53.08 | $152,926.36 |
DisclosureSEC source: 0001104659-07-006560 · a4.xml · nonDerivative · entry 8 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,650 Read SEC document |
| January 30, 2007 Filed Feb 1, 2007 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,881 | $30.20 | $86,994.10 |
DisclosureSEC source: 0001104659-07-006560 · a4.xml · nonDerivative · entry 7 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2007 Filed Feb 1, 2007 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,436 | $53.08 | $76,224.32 |
DisclosureSEC source: 0001104659-07-006560 · a4.xml · nonDerivative · entry 6 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,650 Read SEC document |
| January 30, 2007 Filed Feb 1, 2007 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,436 | $30.24 | $43,428.66 |
DisclosureSEC source: 0001104659-07-006560 · a4.xml · nonDerivative · entry 5 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2007 Filed Feb 1, 2007 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,383 | $53.08 | $73,411.02 |
DisclosureSEC source: 0001104659-07-006560 · a4.xml · nonDerivative · entry 4 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,650 Read SEC document |
| January 30, 2007 Filed Feb 1, 2007 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,383 | $31.43 | $43,463.54 |
DisclosureSEC source: 0001104659-07-006560 · a4.xml · nonDerivative · entry 3 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2007 Filed Feb 1, 2007 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,393 | $53.08 | $73,941.83 |
DisclosureSEC source: 0001104659-07-006560 · a4.xml · nonDerivative · entry 2 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,650 Read SEC document |
| January 30, 2007 Filed Feb 1, 2007 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,393 | $26.88 | $37,441.47 |
DisclosureSEC source: 0001104659-07-006560 · a4.xml · nonDerivative · entry 1 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2006 Filed May 11, 2006 20:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,549 | $0.00 Strike: $24.20 | $0.00 |
DisclosureSEC source: 0001104659-06-033857 · a4.xml · derivative · entry 5 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 1,549 shares Expires 2006-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program. It contains a replacement option feature. Read SEC document |
| May 09, 2006 Filed May 11, 2006 20:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,613 | $0.00 Strike: $23.23 | $0.00 |
DisclosureSEC source: 0001104659-06-033857 · a4.xml · derivative · entry 4 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 1,613 shares Expires 2006-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program. It contains a replacement option feature. Read SEC document |
| May 09, 2006 Filed May 11, 2006 20:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,162 | $42.30 | $133,752.60 |
DisclosureSEC source: 0001104659-06-033857 · a4.xml · nonDerivative · entry 3 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,650 Read SEC document |
| May 09, 2006 Filed May 11, 2006 20:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,549 | $24.20 | $37,485.65 |
DisclosureSEC source: 0001104659-06-033857 · a4.xml · nonDerivative · entry 2 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2006 Filed May 11, 2006 20:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,613 | $23.23 | $37,473.05 |
DisclosureSEC source: 0001104659-06-033857 · a4.xml · nonDerivative · entry 1 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2006 Filed May 2, 2006 21:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 6,525 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001104659-06-030328 · a4.xml · derivative · entry 2 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,525 Underlying: common shares · 6,525 shares Expires 2016-04-27 F2 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program. Read SEC document |
| April 28, 2006 Filed May 2, 2006 21:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-06-030328 · a4.xml · nonDerivative · entry 1 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,650 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 22, 2005 Filed Apr 26, 2005 21:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 5,796 | $0.00 Strike: $47.62 | $0.00 |
DisclosureSEC source: 0001104659-05-018229 · a4.xml · derivative · entry 2 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,796 Underlying: Common shares · 5,796 shares Expires 2015-04-20 F2 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program. Read SEC document |
| April 22, 2005 Filed Apr 26, 2005 21:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-05-018229 · a4.xml · nonDerivative · entry 1 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,523 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| May 03, 2004 Filed May 5, 2004 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock equivalent units · Derivative | 2,652 | $42.32 Strike: $0.00 | $112,232.64 |
DisclosureSEC source: 0001104659-04-012715 · a4.xml · derivative · entry 1 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,597 Underlying: common shares · 2,652 shares Expires not disclosed F1 · derivative.exercise_price: A stock equivalent unit account is maintained for the director for the deferral of director fees and to reflect accrued benefits under a prior retirement plan. These additional stock equivalent units were credited to that account. They resulted from the conversion into stock equivalent units of the deemed distribution of Hospira common stock, in connection with the spin-off of Hospira, Inc. from Abbott, based on the closing price of Abbott and Hospira common stock on May 3, 2004. Units are paid in cash. F1 · kind: A stock equivalent unit account is maintained for the director for the deferral of director fees and to reflect accrued benefits under a prior retirement plan. These additional stock equivalent units were credited to that account. They resulted from the conversion into stock equivalent units of the deemed distribution of Hospira common stock, in connection with the spin-off of Hospira, Inc. from Abbott, based on the closing price of Abbott and Hospira common stock on May 3, 2004. Units are paid in cash. F1 · derivative.exercise_date: A stock equivalent unit account is maintained for the director for the deferral of director fees and to reflect accrued benefits under a prior retirement plan. These additional stock equivalent units were credited to that account. They resulted from the conversion into stock equivalent units of the deemed distribution of Hospira common stock, in connection with the spin-off of Hospira, Inc. from Abbott, based on the closing price of Abbott and Hospira common stock on May 3, 2004. Units are paid in cash. F1 · derivative.expiration_date: A stock equivalent unit account is maintained for the director for the deferral of director fees and to reflect accrued benefits under a prior retirement plan. These additional stock equivalent units were credited to that account. They resulted from the conversion into stock equivalent units of the deemed distribution of Hospira common stock, in connection with the spin-off of Hospira, Inc. from Abbott, based on the closing price of Abbott and Hospira common stock on May 3, 2004. Units are paid in cash. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| April 23, 2004 Filed Apr 27, 2004 19:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 6,699 | $0.00 Strike: $41.20 | $0.00 |
DisclosureSEC source: 0001104659-04-011389 · a4.xml · derivative · entry 2 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,699 Underlying: common shares · 6,699 shares Expires 2014-04-22 F2 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b). It contains a replacement option feature. Read SEC document |
| April 23, 2004 Filed Apr 27, 2004 19:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,577 | $41.20 | $64,972.40 |
DisclosureSEC source: 0001104659-04-011389 · a4.xml · nonDerivative · entry 1 FULLER H LAURANCE · CIK 0001187553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,634 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.